Circadian variations in cardiovascular disease: Chronotherapeutic approaches to the management of hypertension

Reviews in Cardiovascular Medicine

Volumn 5, Issue 3, 2004, Pages 148-155

  Weber, Michael A ^a   Fodera, Susan M ^b  

^a Downstate Health Sciences University   (United States)

^b Bimark Medical Communications   (United States)

Author keywords

Ambulatory blood pressure monitoring; Blood pressure; Chronotherapy; Hypertension

Indexed keywords

ADRENALIN; ALDOSTERONE; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; ATENOLOL; BISOPROLOL; CREATINE KINASE MB; DILTIAZEM; DIURETIC AGENT; ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM; NIFEDIPINE; NORADRENALIN; PROPRANOLOL; RAMIPRIL; RENIN; VERAPAMIL;

ACUTE DISEASE; ADRENERGIC SYSTEM; AROUSAL; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; HEART HEMODYNAMICS; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; PHYSICAL ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SILENT MYOCARDIAL ISCHEMIA; STROKE; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; CHRONOTHERAPY; CIRCADIAN RHYTHM; DISEASE MANAGEMENT; HUMANS; HYPERTENSION;

EID: 4544259701     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet. 1978;1:795-797.
2. Weber MA. The 24-hour blood pressure pattern. Does it have implications for morbidity and mortality? Am J Cardiol. 2002;89 (suppl):27A-33A.
3. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit. 2001;6:63-72
4. Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency Of onset of acute myocardial infarction. N Engl J Med. 1985; 313:1315-1322.
5. Willich SN, Linderer T, Wegascheider K, et al. Increased morning incidence of myocardial infarction in the ISAM study. Absence with prior beta-adrenergic blockade. ISAM study group. Circulation. 1989;80:853-858.
6. Thompson DR, Blandford RL, Sutton TW, Marchant PR. Time of onset of chest pain in acute myocardial infarction. Int J Cardiol. 1985;7:139-146.
7. Goldberg RJ, Brady P, Muller JE, et al. Time of onset of symptoms of acute myocardial infarction. Am J Cardiol. 1990;66:140-144.
8. Muller JE, Ludmer PL, Willich SN, et al. Circadian variation in the frequency of sudden cardiac death. Circulation. 1987;75:131-138.
9. Willich SN, Levy D, Rocco MB, et al. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol. 1987;60:801-806.
10. Marler JR, Price TR, Clark GL, et al. Morning increase in onset of ischemic stroke. Stroke. 1989;20:473-476.
11. Argentino C, Toni D, Rasura M, et al. Circadian variations in the frequency of ischemic stroke. Stroke. 1990;21:387-389.
12. Elliott WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens. 2001; 14:291S-295S.
13. Glasser SP. Circadian variations and chronotherapeutic implications for cardiovascular management. A focus on COER verapamil. Heart Dis. 1999;1:226-232.
14. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987;316:1514-1518.
15. Gosse P, Cipriano C, Bemurat L, et al. Prognostic significance of blood pressure measured on rising. J Hum Hypertens. 2001; 15:413-417.
16. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. A prospective study. Circulation. 2003;107:1401-1406.
17. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
18. Svensson P, Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: A HOPE sub-study. Hypertension. 2001;38:e28-e32.
19. Weber MA, Drayer JI, Nakamura DK, Wyle FA. The circadian blood pressure pattern in ambulatory normal subjects. Am J Cardiol. 1984; 54:115-119.
20. Weber MA, Smith DH, Neutel JM, Cheung DG. Applications of ambulatory blood pressure monitoring in clinical practice. Clin Chem. 1991;37:1880-1884.
21. Neutel JM, Smith DH, Weber MA. What are the approaches for evaluating antihypertensive treatment by 24 hour ambulatory blood pressure monitoring? Blood Press Monit. 1999;4:S23-S28.
22. Deedwania PC, Nelson JR. Pathophysiology of silent myocardial ischemia during daily life. Hemodynamic evaluation by simultaneous electrographic and blood pressure monitoring. Circulation. 1990;82:1296-1304.
23. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539-546.
24. Clement DL, De Buyzere ML, De Bacquer DA, et al. Office versus ambulatory pressure study investigators. N Engl J Med. 2003;348:2407-2415.
25. Neutel JM, Smith DH, Ram CV, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med. 1993;94:181-187.
26. Neutel JM, Schnaper H, Cheung DG, et al. Antihypertensive etfects of β-blockers administered once-daily: 24-hour measurements. Am Heart J. 1990;120:166-171.
27. Lorimer AR, Lyons D, Fowler G, et al. Differences between amlodipine and lisinopril in control of clinic and 24-hour ambulatory blood pressure. J Hum Hypertens. 1998;12:411-416.
28. Smith DHG, Neutel JM, Weber MA. A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. Am J Hypertens. 2001; 14:14-19.
29. Neutel JM, Alderman M, Anders RJ, Weber MA. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. Am Heart J. 1996;132:1202-1206.
30. White WB, Anders RJ, MacIntyre JM, et al. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Am J Cardiol. 1995;76:375-380.
31. Glasser SP, Neutel JM, Gana TJ, Albert KS. Efficacy and safety of a once daily graded release diltiazem formulation in essential hypertension. Am J Hypertens. 2003;16:51-58.
32. Sica D, Frishman WH, Manowitz N. Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (Innopran XL™), a new chronotherapeutic formulation. Heart Dis. 2003;5:176-181.
33. White WB, Black HR, Weber MA, et al. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cordial. 1998;81:424-431.
34. White WB, Sica DA, Calhoun D, et al. Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Am Heart J. 2002;144:657-665.
35. Bakris G, Sica D, Ram V, et al. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens. 2002;15:53-57.
36. Neutel JM, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens. 2003;5:58-63.
37. Black HR, Elliott WJ, Grandits G, et al, for the CONVINCE Study Group. Principle Results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. JAMA. 2003;289:2073-2082.